Monitoring adverse drug reactions is becoming a priority for public health programs involved in large scale-ups of new essential medicines. Under an interagency agreement between the US Food and Drug Administration and the US Agency for International Development (USAID), the SPS program assessed pharmacovigilance activities of 32 PHPs in sub-Saharan Africa. Poster displayed at the International AIDS 2012 conference in Washington DC, 22nd-27th July 2012.